Difference between revisions of "CASC8"

From LncRNAWiki
Jump to: navigation, search
(Created page with "''CASC8'':cancer susceptibility candidate 8,located in 8q24.21 region, is suggested with cancer, such as colorectal cancer, prostate cancer, intestinal tumor,<ref name="re...")
 
(Blanked the page)
 
Line 1: Line 1:
''CASC8'':cancer susceptibility candidate 8,located in 8q24.21 region, is suggested with cancer, such as colorectal cancer, prostate cancer, intestinal tumor,<ref name="ref1" /> gastric cancer<ref name="ref2" />
 
  
==Annotated Information==
 
===Name===
 
''CASC8'':cancer susceptibility candidate 8(non-protein coding)
 
 
''CARLo-1'',LINC008600,”long intergenic non-protein coding RNA 860” <ref name="ref1" />
 
 
===Characteristics===
 
Seven lncRNAs are located in the 8q24.21 gene desert. The region including CARLo-1∼6 <ref name="ref1" />
 
 
===Function===
 
[[File: Function of CARLo-5 in cell proliferation through cell-cycle regulation..jpg|right|thumb|400px|'''Function of CARLo-5 in cell proliferation through cell-cycle regulation.''' <ref name="ref1" />.]]
 
 
Inhibition of CARLo-5 dramatically reduced the number of cells and colonies in vitro, indicating a role of CARLo-5 in cell transformation. CARLo-5 is not only overexpressed in tumors but also involved in tumorigenesis. <ref name="ref1" />
 
CASC8 may presumably play a key role in modulating the recruitment of general transcription factors on the promoter of its cognate gene, POU5F1B, which was found to be a putative cancer susceptibility gene. It is biologically plausible that allele of rs10505477 further alters the fine turning interactions between the CASC8 and POU5F1B. <ref name="ref2" />.
 
 
===Regulation===
 
CASC8 regulated by rs10505477 ,which was involved in clinical outcomes of gastric cancer, act as a cancer susceptibility candidate. <ref name="ref2" />
 
 
===Diseases===
 
* colorectal cancer, prostate cancer, intestinal tumor<ref name="ref1"/>,gastric cancer<ref name="ref2"/>
 
 
===Expression===
 
CARLo-5 is overexpressed in CRC and involved in oncogenic transformation and tumor incidence.<ref name="ref1" />
 
 
{| class='wikitable' style="text-align:center"
 
|-
 
! | Target lncRNA
 
! | Use
 
! | Sequence
 
|-
 
| rowspan="1"|CARLo-1 v1&3
 
| | 5′ RACE
 
 
5′ nested PCR and sequencing
 
 
Internal-F and sequencing
 
 
Internal-R and sequencing
 
3′ RACE
 
3′ nested PCR and sequencing
 
 
| |GGCAGGTTGTGTGTCACGCCCTCCACT
 
ATGTTTCATTGGCTGAAGCTCAATTG
 
CCTCAGGAACACACATGGATGATTCT
 
AAAGAGTATGGAGGCTTGAACATGGC
 
AGTGGAGGGCGTGACACACAACCTGCC
 
GCCATGTTCAAGCCTCCATACTCTTT<ref name="ref1" />
 
|-
 
| rowspan="1"|CARLo-1 v2&4
 
| | 5′ RACE
 
5′ nested PCR and sequencing
 
Internal-F and sequencing
 
Internal-R and sequencing
 
3′ RACE
 
3’nested PCR and sequencing
 
 
| | GCTCCTGGTCCATGCCATTCATCAATTG
 
GCTGAGGACAGAAGGCATTGGTCT
 
GAGCATCCGAATAAATAAACATACAAATGC
 
ATTTTTCACCTGCTTCAGTGCCATTGT
 
GAGACCAATGCCTTCTGTCCTCAGC
 
AATTGATGAATGGCATGGACCAGG<ref name="ref1" />
 
|-
 
| rowspan="1"|CARLo-2
 
| | 5′ RACE
 
 
5′ nested PCR and sequencing
 
Internal-F and sequencing
 
 
Internal-R and sequencing
 
 
3′ RACE
 
 
3′ nested PCR and sequencing
 
 
| | CCTTGACTTGAGCCCAGGTCACCATGC
 
ACGTCTTCTCTTGGCTCCTCTGGAT
 
AAACTATTGATGCAGTGTCCAAGGTGG
 
ACATCAGTTAAAAGGCCAACAGGAACC
 
GCATGGTGACCTGGGCTCAAGTCAAGG
 
CTTATTTCTCTGCTGAACCATCACA<ref name="ref1" />
 
|-
 
| rowspan="1"|CARLo-3
 
| | CARLo-3
 
| | TGGGCCTAGTACTTGGAGACGGGGACTG
 
TTGGATGATAGTGAAGGTGAACGTCTCT
 
AACGAAGAGCATCACCATTTCCACCA
 
ACTCTCCTAATGGGCCTAGTACTTGGAGAC
 
AACGAAGAGCATCACCATTTCCACCACC
 
AGAGACGTTCACCTTCACTATCATCCAA<ref name="ref1" />
 
|-
 
| rowspan="1"|CARLo-4
 
| | 5′ RACE
 
 
5′ nested PCR and sequencing
 
Internal-F and sequencing
 
 
Internal-R and sequencing
 
3′ RACE
 
 
3′ nested PCR and sequencing
 
 
| | GTGACAGACGGAGTGCTGATGCCTCTGG
 
AATCTCTTCACATTGTGGAGTTTCTCCTC
 
ATCTAGCAAATAGGCATCTGTCACAGAAAATAGA
 
ATCAGCCTAACCAGCACGCATAAACTAAAC
 
CCAGAGGCATCAGCACTCCGTCTGTCAC
 
TCTGTCACTATTGGCATCCTGTGACA<ref name="ref1" />
 
|-
 
| rowspan="1"|CARLo-5
 
| | 5′ RACE
 
5′ nested PCR and sequencing
 
Internal-F and sequencing
 
Internal-R and sequencing
 
3′ RACE
 
3′ nested PCR and sequencing
 
 
| | GGGTTGAGAAGGGGTGAAGGGACACTGG
 
AAGTGAAGCTGGGAAGTTTGCACTTG
 
GCCACAAATCAACAACAACAACAACAA
 
AGAGTGATGCCAAGGCTGTTATTGTCAA
 
CCAGTGTCCCTTCACCCCTTCTCAACCC<ref name="ref1" />
 
|-
 
| rowspan="1"|CARLo-6
 
| | 5′ RACE
 
5′ nested PCR and sequencing
 
Internal-F and sequencing
 
Internal-R and sequencing
 
3′ RACE
 
3′ nested PCR and sequencing
 
 
| | GGGTGCCATCACAGTCAGTTTGGACAGC
 
CTTGAATGCTATCAGGGAAGCTAGAGTG
 
CTTAGAATTGGAGTGCCTGGGTTAGAA
 
GCAGTCATTCAGGAATTGAAGCTGATA
 
GCTGTCCAAACTGACTGTGATGGCACCC
 
AGACAGACAGCGATGCCACATGTT<ref name="ref1" />
 
|}
 
 
===Sequence===
 
>gi|211971085|ref|NR_024393.1| Homo sapiens cancer susceptibility candidate 8 (non-protein coding) (CASC8), transcript variant 2, long non-coding RNA
 
<dnaseq>TGAACCACCCCAGGCCCTTTGCACCTGCTATTCCCTCTCCTCAGCATGCTCTGCCCCAGACAATTGCAAT
 
GCTAACTTCTTACTTCCTTCAGGTTTCACTCAGAAATGACTTTCTCAGTGGGGTCTCCCATGACCATTTT
 
ATTTAAGATTTCAACTACTTTGCCAGTATTTCACTTCTCCTCCCTTGATCTTTTCTTCCAAGCACTCACT
 
GCCCTCTTGCACACTGTATCTTTTACTTATTTATCTTGTTCAGTTTCTGCCTGCCTCACCTGCCTCACCA
 
CAGTGTACATTTCACGAGGGCAGGGATTTTGTCTGTTTTGTTGATTGCTGTAGCCCTGGCATCTTGGGCA
 
GTGCCAGCACCTGTTAGCATTAAATACATATTTACTGAATGAATGAGTGGCTTCATGCTTAAAAGCAAGA
 
AGAGAGACCTTCATAGAGAAGTAGGAAAATGAATTGTTGCACAAATAAAGGGCCATGTAATGAGAGAGAG
 
AGAGCAAGAGAAAGAGCAAACAATTAAGGAGCAGCAGTGGCTTCCTGCAGGGGAGACCAATGCCTTCTGT
 
CCTCAGCGGAAACAGCTTGGCATTCTTCCAATTGATGAATGGCATGGACCAGGAGCACTAGTTATCTTCA
 
GCTTCTGAGCATCCGAATAAATAAACATACAAATGCATAACATAAAATAAATTCAAATTACAAATGAGAA
 
AACCAATCTAGGTTACCGGCAAGTCCTATGACTTGATGTGGAGGCCTGGAAGTGCATCCTTGAATCTTGC
 
AATGCAGTGAGCCAAGGAGCAATGAGAGGCCACATGAATAACCGGGCCAGTGACAAGACACATGTCCTCC
 
TCCTTGCTGGTATACACCAGAATGCCCCGCATGCAGCGAATGCTCAAAAAGTGTTGGTGGAAGTGACAGA
 
ATTCCATCACCATTAAACACAACCAGTGTTGCGGTTGACAATGGCACTGAAGCAGGTGAAAAATCCGTAC
 
AGCAGCTTCTGTCTTTGAAGAGTTTGCAGCCTCTTGAAGAGGGTTTAGAGGTTAAAAAAAGGACCCAGGC
 
TGATAGGGCCGCTACCATTTGGAAAGTGACAAGAGGAAGAGAGAGAATGAAACAACAGTAAGCACTGGCT
 
CTCAGCTTCTACCTGAAGAGACAAACATTGCTTTCACTTACATTTCACTGGCCAAATCAAGCCCATGGCA
 
ACAATTGAGTTCAAAAGCATAAGGAGGTATCTGGAAGGAAGAGAATCAGAAAATTTCTGATGAGCCTCAC
 
TGACTACCTTCAGGGCAAAAAGGAAGAGAGGCACTCCAGATCAGAGATCTGCATTGGAAACTCCTTGAGA
 
ACCAGAAGGGTATGCTGTATTTTTGTAACTGTGAGGAGCCCAGAAAGACTGAAGCCCAAATAAAATTCCT
 
TTATTCAATATT
 
</dnaseq>
 
 
==Labs working on this lncRNA==
 
* Department of Molecular Virology, Immunology and Medical Genetics andDepartment of Anesthesiology, Wexner Medical Center, and Department of Neurological Surgery, The Ohio State University, Columbus, OH, 43210; <ref name="ref1" />.
 
 
==References==
 
<references>
 
<ref name="ref1"> Kim T, Cui R, Jeon YJ, Lee JH, Lee JH, Sim H, et al. Long-range interaction and correlation between MYC enhancer and oncogenic long noncoding RNA CARLo-5[J]. Proceedings of the National Academy of Sciences of the United States of America. 2014,111(11):4173-8</ref>(1)
 
<ref name="ref2"> Ma G, Gu D, Lv C, Chu H, Xu Z, Tong N, et al. Genetic variant in 8q24 is associated with prognosis for gastric cancer in a Chinese population[J]. Journal of gastroenterology and hepatology.</ref>(2)
 
</references>
 
 
[[Category: Antisense]]
 

Latest revision as of 07:15, 2 April 2015